El Fassi Daniel, Nielsen Claus Henrik, Hegedüs Laszlo
Odense Universitetshospital, Endokrinologisk Afdeling M.
Ugeskr Laeger. 2008 Jun 9;170(24):2128-30.
The current medical treatment options for Graves' ophthalmopathy (GO) are unsatisfactory. Recent treatment of GO patients with the B-lymphocyte depleting monoclonal antibody rituximab or with the anti-tumor necrosis factor-alpha agents etanercept and infliximab has shown promising results. We discuss the use of these and other biological agents targeting B lymphocytes, T-lymphocyte interaction with antigen-presenting cells, or cytokines in the future treatment of GO.
目前针对格雷夫斯眼病（GO）的医学治疗选择并不令人满意。最近用B淋巴细胞清除单克隆抗体利妥昔单抗或抗肿瘤坏死因子-α药物依那西普和英夫利昔单抗治疗GO患者已显示出有希望的结果。我们讨论这些以及其他靶向B淋巴细胞、T淋巴细胞与抗原呈递细胞相互作用或细胞因子的生物制剂在GO未来治疗中的应用。
